neuromyelitis

The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD). The approval for the treatment comes as a monotherapy or in combination with immunosuppressive therapy. ...